510 related articles for article (PubMed ID: 21933306)
1. Leishmaniasis chemotherapy--challenges and opportunities.
Croft SL; Olliaro P
Clin Microbiol Infect; 2011 Oct; 17(10):1478-83. PubMed ID: 21933306
[TBL] [Abstract][Full Text] [Related]
2. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
3. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
4. Post-kala-azar dermal Leishmaniasis and uveitis in an HIV-positive patient.
Ramos A; Cruz I; Muñez E; Salas C; Fernández A; Alvarez-Espejo T
Infection; 2008 Mar; 36(2):184-6. PubMed ID: 18327683
[No Abstract] [Full Text] [Related]
5. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
6. Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.
Pandey K; Das VN; Singh D; Das S; Lal CS; Verma N; Bimal S; Topno RK; Siddiqui NA; Verma RB; Sinha PK; Das P
J Clin Microbiol; 2012 Apr; 50(4):1478-9. PubMed ID: 22278840
[TBL] [Abstract][Full Text] [Related]
7. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
[TBL] [Abstract][Full Text] [Related]
8. Treatment of leishmaniasis with miltefosine: 2008 status.
Berman JJ
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
10. Current scenario of drug development for leishmaniasis.
Croft SL; Seifert K; Yardley V
Indian J Med Res; 2006 Mar; 123(3):399-410. PubMed ID: 16778319
[TBL] [Abstract][Full Text] [Related]
11. Injectable paromomycin for Visceral leishmaniasis in India.
Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
[TBL] [Abstract][Full Text] [Related]
12. Leishmaniasis: an update of current pharmacotherapy.
Sundar S; Chakravarty J
Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
[TBL] [Abstract][Full Text] [Related]
13. Post-kala-azar dermal leishmaniasis in HIV-coinfected individuals: problems in diagnosis and treatment.
Ramesh V; Avishek K; Salotra P
Int J Dermatol; 2015 Jan; 54(1):116-20. PubMed ID: 25209701
[No Abstract] [Full Text] [Related]
14. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging medications for the treatment of leishmaniasis.
Chakravarty J; Sundar S
Expert Opin Pharmacother; 2019 Jul; 20(10):1251-1265. PubMed ID: 31063412
[TBL] [Abstract][Full Text] [Related]
16. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
[TBL] [Abstract][Full Text] [Related]
17. Short report: Treatment failure due to mixed infection by different strains of the parasite Leishmania infantum.
Antoniou M; Doulgerakis C; Pratlong F; Dedet JP; Tselentis Y
Am J Trop Med Hyg; 2004 Jul; 71(1):71-2. PubMed ID: 15238692
[TBL] [Abstract][Full Text] [Related]
18. Treatment of visceral leishmaniasis in 2004.
Murray HW
Am J Trop Med Hyg; 2004 Dec; 71(6):787-94. PubMed ID: 15642973
[TBL] [Abstract][Full Text] [Related]
19. Short communication: post-kala-azar dermal leishmaniasis--an appraisal.
Ramesh V; Singh R; Salotra P
Trop Med Int Health; 2007 Jul; 12(7):848-51. PubMed ID: 17596251
[TBL] [Abstract][Full Text] [Related]
20. Developments in the treatment of visceral leishmaniasis.
den Boer ML; Alvar J; Davidson RN; Ritmeijer K; Balasegaram M
Expert Opin Emerg Drugs; 2009 Sep; 14(3):395-410. PubMed ID: 19708817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]